January 23, 2020 / 6:41 AM / a month ago

BRIEF-Orion: Marketing Authorization For Darolutamide In Japan

Jan 23 (Reuters) - Orion Corp:

* MARKETING AUTHORIZATION GRANTED FOR DAROLUTAMIDE IN JAPAN

* JAPANESE MINISTRY OF HEALTH, LABOR AND WELFARE GRANTED MARKETING AUTHORIZATION FOR DAROLUTAMIDE, UNDER BRAND NAME NUBEQA

* IT IS CURRENTLY NOT APPROVED BY EUROPEAN MEDICINES AGENCY

* JAPANESE MINISTRY OF HEALTH, LABOR AND WELFARE (MHLW) HAS GRANTED MARKETING AUTHORIZATION FOR DAROLUTAMIDE, UNDER BRAND NAME NUBEQA®, FOR TREATMENT OF MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Source text for Eikon:

Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below